Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712985 · ClinicalTrials.gov registry record · Phase 3
Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)
A Phase 3 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 18
- Enrollment target
NCT00712985 is a Phase 3 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT00712985, a Phase 3 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this research is to establish if a once a year dose of Zoledronic Acid is sufficient to suppress and maintain urine and serum bone density markers (NTx) and serum CTx within normal range at 12 months post-dosing in postmenopausal early breast cancer patients receiving additional treatment with non-steroidal aromatase inhibitors.
Interventions
- DRUG Zometa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00712985
The ClinicalTrials.gov registry entry for NCT00712985 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zometa is the first listed.
NCT00712985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00712985 about?
NCT00712985 is a clinical study titled "Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)". The purpose of this research is to establish if a once a year dose of Zoledronic Acid is sufficient to suppress and maintain urine and serum bone density markers (NTx) and serum CTx within normal range at 12 months post-dosing in postmenopausal early breast cancer patients receiving additional treat...
What is the current status of trial NCT00712985?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2005-09. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00712985?
The interventions under investigation include: Zometa (DRUG).
Who is sponsoring clinical trial NCT00712985?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.